BriaCell Therapeutics Corp
BCT
Company Profile
Business description
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company’s targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Contact
235-15th Street
Suite 300, 3rd Floor, Bellevue Centre
West Vancouver
VancouverBCV7T 2X1
CANT: +1 888 485-6340
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 July 2027
Employees
4
Stocks News & Analysis
stocks
5 star fully franked ASX dividend payer
Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,886.60 | 35.90 | 0.41% |
| CAC 40 | 8,101.37 | 22.89 | 0.28% |
| DAX 40 | 25,566.26 | 191.84 | 0.76% |
| Dow JONES (US) | 51,481.51 | 347.11 | -0.67% |
| FTSE 100 | 10,724.51 | 39.63 | 0.37% |
| HKSE | 24,523.57 | 118.94 | -0.48% |
| NASDAQ | 26,820.38 | 248.34 | -0.92% |
| Nikkei 225 | 65,481.27 | 396.35 | -0.60% |
| NZX 50 Index | 13,683.63 | 147.05 | -1.06% |
| S&P 500 | 7,683.69 | 59.72 | -0.77% |
| S&P/ASX 200 | 8,709.30 | 29.60 | 0.34% |
| SSE Composite Index | 3,830.45 | 6.83 | 0.18% |